APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024

• DOI: 10.1007/s12072-024-10732-z
• Publication Date: 2024-11-21T05:23:31Z
• Authors: George Lau; Shuntaro Obi; Jian Zhou; Ryosuke Tateishi; Shukui Qin; Haitao Zhao; Motoyuki Otsuka; Sadahisa Ogasawara; Jacob George; Pierce K. H. Chow; Jianqiang Cai; Shuichiro Shiina; Naoya Kato; Osamu Yokosuka; Kyoko Oura; Thomas Yau; Stephen L. Chan; Ming Kuang; Yoshiyuki Ueno; Minshan Chen; Ann-Lii Cheng; Gregory Cheng; Wan-Long Chuang; Oidov Baatarkhuu; Feng Bi; Yock Young Dan; Rino A. Gani; Atsushi Tanaka; Wasim Jafri; Ji-Dong Jia; Jia-Horng Kao; Kiyoshi Hasegawa; Patrick Lau; Jeong Min Lee; Jun Liang; Zhenwen Liu; Yinying Lu; Hongming Pan; Diana A. Payawal; Salimur Rahman; Jinsil Seong; Feng Shen; Gamal Shiha; Tianqiang Song; Hui-Chuan Sun; Tsutomu Masaki; Ekaphop Sirachainan; Lai Wei; Jin Mo Yang; Jose D. Sallano; Yanqiao Zhang; Tawesak Tanwandee; AKadir Dokmeci; Shu-sen Zheng; Jia fan; Sheung-Tat Fan; Shiv Kumar Sarin; Masao Omata
• Keywords: Systemic therapy; Targeted Therapy

In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation disease progression in those with not eligible resection failed locoregional therapy. recent few years, new targeted therapy immune-checkpoint inhibitors have been registered as systemic address these issues. Notably, forms therapy, either first-line second-line unresectable now available. New data also emerging use prevent retard future, further implementation other immunotherapy expected bring paradigm management carcinoma. insight related immune-related adverse events has allso enabled optimization therapeutic approach patients The purpose this clinical practice guideline provide an up-to-date recommendation based on evidence experience from expert key opinion leaders field Three questions will be addressed, namely: (1) Which should considered therapy? (2) used? (3) How patient planned immune checkpoint-based managed monitored?